|
answer text |
<p>Through its technology appraisal programme, the National Institute for Health and
Care Excellence (NICE) provides independent, evidence-based guidance for the National
Health Service on whether drugs and treatments represent a clinically and cost effective
use of NHS resources. NICE is appraising Brentuximab for this indication and recently
consulted stakeholders on its draft recommendations. Brentuximab is currently available
to NHS patients with relapsed and refractory Hodgkin lymphoma through the Cancer Drugs
Fund.</p>
|
|